| Literature DB >> 25729244 |
Hyo Jin Choi1, Chan Hee Lee2, Joo Hyun Lee3, Bo Young Yoon3, Hyoun Ah Kim4, Chang Hee Suh4, Sang Tae Choi5, Jung Soo Song5, HoYeon Joo6, Sung Jae Choi7, Ji Soo Lee8, KiChul Shin9, Jae-Bum Jun10, Han Joo Baek1.
Abstract
The object of this study was to evaluate the seasonality of gout in Korea. We retrospectively examined data from 330 patients seen at nine rheumatology clinics, treated with urate lowering therapy (ULT) more than one year after stopping prophylactic medication. Demographic data, clinical and laboratory features, and seasonality of gout onset and flares were collected. Season was classified in three-month intervals. The mean age was 52.2 yr and mean disease duration was 26.8 months. The male to female count was 318:12. The onset of acute gouty attacks was obtained in 256 patients. Gout developed most commonly in summer season (36.7%) (P<0.001) and in June (15.6%, P=0.002). During ULT, there were 147 (male 97.3%) gout flares. Although there was no statistically significant difference, gout flares were more common in summer (30.6%). Aggravating factors were identified in 57 flares: alcohol (72.0%) was most common. In the patients who attained target serum uric acid (<6 mg/dL) at the end of prophylaxis, gout flares were high in fall (35.8%) and September (17.0%). In Korea, the summer is most common season of gout onset and there is a tendency for gout flares to increase during ULT in summer/fall season.Entities:
Keywords: Flares; Gout Onset; Korea; Seasonality; Summer
Mesh:
Substances:
Year: 2015 PMID: 25729244 PMCID: PMC4330476 DOI: 10.3346/jkms.2015.30.3.240
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Demographic and baseline characteristics
ULT, urate lowering therapy; NSAIDs, non-steroidal anti-inflammatory drugs; CCr, calculated creatinine.
Seasonality of gout onset
*By Goodness of fit test.
Monthly distribution of gout onset
P=0.002, by Goodness of fit test.
Seasonality of gout flares in the patients with urate lowering therapy after prophylaxis ended
*By Goodness of fit test.
Fig. 1The seasons and months of gout flares. Those in all episodes (A, B) and in patients who attained target serum uric acid at the end of prophylaxis (C, D).